The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11–13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.
Purpose Sentinel lymph node (SLN) biopsy may be used to target lymph node metastases in patients with early cervical cancer. Whether SLN biopsy only is acceptable in the staging and surgical management of early cervical cancer remains unknown. This prospective multicenter study (SENTICOL [Ganglion Sentinelle dans le Cancer du Col]) assessed the sensitivity and negative predictive value (NPV) of SLN biopsy. Patients and Methods Adults with cervical carcinoma who met the International Federation of Gynecology and Obstetrics criteria for stage IA1 with lymphovascular space invasion to stage IB1 underwent technetium 99 lymphoscintigraphy and Patent Blue injection followed by laparoscopic lymph node mapping, SLN removal, and lymph node dissection. Only surgeons trained in SLN biopsy in cervical carcinoma participated in the study. SLNs and nonsentinel lymph nodes underwent routine staining. Negative SLNs were subjected to ultrastaging. The reference method was pelvic and/or para-aortic lymphadenectomy with histologic examination of all nodes. Results One hundred forty-five patients were enrolled, and 139 were included in a modified intention-to-diagnose analysis. Intraoperative radioisotope-blue dye mapping detected at least one SLN in 136 patients (97.8%; 95% CI, 93.8% to 99.6%), 23 of whom had true-positive results and two who had false-negative results, yielding 92.0% sensitivity (23 of 25; 95% CI, 74.0% to 99.0%) and 98.2% NPV (111 of 113; 95% CI, 74.0% to 99.0%) for node metastasis detection. No false-negative results were observed in the 104 patients (76.5%) in whom SLN were identified bilaterally. Conclusion Combined labeling for node mapping was associated with high rates of SLN detection and with high sensitivity and NPV for metastasis detection. However, SLN biopsy was fully reliable only when SLNs were detected bilaterally.
Non-epithelial ovarian tumours account for approximately 10% of all ovarian cancers. Malignant germ cell tumours (GCTs) occur mainly in young women whereas the most common type of sex cord-stromal tumours (SCSTs), i.e. granulosa cell tumour, occurs more often in middle age and in postmenopausal women [1]. Malignant GCTs represent 5% of all ovarian cancers and 80% of the preadolescent malignant ovarian tumours. SCSTs are rare neoplasms that account for approximately 3%–5% of ovarian malignancies and the majority of ovarian tumours with endocrine manifestations. The yearly-adjusted incidence rate is 3.7/1 000 000 and 2.1/1 000 000 women for GCTs and SCSTs, respectively [1]. Small cell carcinoma of the ovary (SCCO) usually affects young women and children [2] with a very low incidence (less than 1% of ovarian cancers) [1]. Unlike GCTs, SCSTs and steroid cell tumours are unilateral and occur over a wide range of age; for instance, granulosa cell tumours and thecomas are found mainly in peri- and postmenopausal women, whereas juvenile granulosa cell tumours, Sertoli cell tumours and Sertoli–Leydig cell tumours (SLCTs) usually develop in adolescents and young females in whom maintenance of fertility is important [3].